Cloning of the met oncogene from chemically transformed cells was first reported in 1984 (1) . Its protooncogene was subsequently reported to have the structure of a receptor tyrosine kinase (2), and its ligand was shown to be hepatocyte growth factor (HGF) in 1991 (3) . By the end of 1995, when the Drug Discovery team at SUGEN decided to try to identify a small-molecule kinase inhibitor for cMet, more than 300 articles on various aspects of c-Met biology had been published. We considered it a compelling target because activation of c-Met kinase induced important tumor responses such as angiogenesis, epithelial-mesenchymal transformation, invasion, and metastasis, and because c-Met was associated with many different types of cancer.
In early 1996, efforts began at SUGEN to develop biochemical and cellular screening assays to identify a c-Met kinase inhibitor, and we went through several iterations before we had suitable reagents for testing compounds in biochemical assays. SUGEN was a pioneer in the field of kinase inhibitors and developed tools in the early days of kinase chemistry to identify and optimize inhibitors. Molecular modeling and a targeted synthetic effort enabled us to rapidly identify the firstgeneration c-Met kinase inhibitors that were the subject of our original article in Molecular Cancer Therapeutics.
The compounds described in this article had reasonable potency and good selectivity for inhibition of c-Met kinase and inhibited HGF-induced cell functions relevant for cancer. Further modification of the core scaffold led to the second generation of a c-Met kinase inhibitor, PHA-665752, which demonstrated inhibitory effects on c-Met phosphorylation and tumor growth in a xenograft model (4) . Although PHA-665752 exhibited properties more suitable for use in vivo, these properties were inadequate for its success as a drug. This led to the decision to pursue alternative chemical scaffolds with better pharmaceutical properties. Importantly, our early c-Met inhibitors continued to serve as tool compounds for further target validation and mechanism-of-action studies in industry and academic laboratories.
The knowledge gained from our work on the pyrrolindolinone chemical series influenced the design and development of many other c-Met inhibitors, including crizotinib (PF2341066), a dual inhibitor of c-Met and anaplastic lymphoma kinases (ALK; ref. Although much of the initial clinical success was observed in patients whose tumors contained ALK rearrangements (6) (7) (8) , crizotinib has also demonstrated activity in a patient with a non-small cell lung cancer containing a MET amplification (9) . Studies to further explore the activity of crizotinib in patient populations exhibiting dysregulated MET are ongoing. Several other c-Met kinase inhibitors are also in clinical development. It is hoped that these or other therapeutics may lead to more treatment options for cancer patients.
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